Get the Stockscreener App
2.60
0.19%
0.005
Alpha Tau Medical Ltd stock is traded at $2.60, with a volume of 30,096.
It is up +0.19% in the last 24 hours and up +3.17% over the past month.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company derives maximum revenue from Israel.
See More
Previous Close:
$2.595
Open:
$2.64
24h Volume:
30,096
Relative Volume:
0.57
Market Cap:
$223.06M
Revenue:
-
Net Income/Loss:
$-29.64M
P/E Ratio:
-6.0465
EPS:
-0.43
Net Cash Flow:
$-39.43M
1W Performance:
-1.52%
1M Performance:
+3.17%
6M Performance:
+14.04%
1Y Performance:
+4.42%
1-Day Range:
$2.57
$2.64
1-Week Range:
$2.50
$2.74
52-Week Range:
$1.75
$4.3866
Alpha Tau Medical Ltd Stock (DRTS) Company Profile
Compare DRTS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DRTS
Alpha Tau Medical Ltd
|
2.60 | 223.06M | 0 | -29.64M | -39.43M | -0.43 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.92B | 3.81B | -644.79M | -669.77M | -6.24 |
Alpha Tau Medical Ltd Stock (DRTS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-15-23 | Initiated | Citigroup | Buy |
| Apr-24-23 | Initiated | H.C. Wainwright | Buy |
| Apr-14-22 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-08-22 | Initiated | Piper Sandler | Overweight |
| Apr-04-22 | Initiated | Citigroup | Buy |
Alpha Tau Medical Ltd Stock (DRTS) Latest News
Alpha Tau Medical’s (DRTS) Buy Rating Reiterated at HC Wainwright - Defense World
HC Wainwright Lifts Earnings Estimates for Alpha Tau Medical - Defense World
Latham & Watkins Advises Alpha Tau Medical in US$36.9 Million Registered Direct Offering - Latham & Watkins LLP
Alpha Tau Medical Ltd: Strategic Investment and Promising Clinical Milestones Drive Buy Rating - TipRanks
Alpha Tau Medical (DRTS) Secures $36.9M in Direct Offering with Oramed Pharmaceuticals | DRTS Stock News - GuruFocus
Oramed Invests $36.9 Million In Alpha Tau For Strategic Growth - Finimize
Oramed invests $36.9 million in Alpha Tau cancer therapy By Investing.com - Investing.com
Alpha Tau Medical (DRTS) Secures $36.9M in Strategic Stock Sale - GuruFocus
Oramed Invests in Alpha Tau (DRTS) with Strategic Partnership | - GuruFocus
Alpha Tau Closes $36.9 Mln Offering And Forms Strategic Alliance With Oramed Pharmaceuticals - Nasdaq
Oramed Completes $36.9 Million Strategic Investment in Alpha Tau Medical - marketscreener.com
Alpha Tau enters strategic marketing alliance with Oramed - TipRanks
Alpha Tau Announces Closing of $36.9 Million Registered - GlobeNewswire
Alpha Tau's $37M Deal Unlocks Major Growth: 4 US Trials and Marketing Alliance Signal Expansion - Stock Titan
Oramed Closes $36.9M Strategic Investment in Alpha Tau Medical - citybiz
Alpha Tau Announces Closing of $36.9 Million Registered Direct Offering and Strategic Marketing Alliance with Oramed Pharmaceuticals - Yahoo Finance
Alpha Tau Medical (NASDAQ:DRTSW) Shares Up 2.3% – Still a Buy? - Defense World
Comparing ICU Medical (NASDAQ:ICUI) and Alpha Tau Medical (NASDAQ:DRTS) - Defense World
High Intensity Focused Ultrasound (HIFU) Market to Witness - openPR.com
Alpha Emitter Market to Witness Massive Growth by 2032 | Actinium - openPR.com
FDA Grants Rare Pediatric Designation to Treatment With NEO100 in Brain Cancer - Curetoday
Alpha Tau Medical (NASDAQ:DRTSW) Shares Down 7.4% – Time to Sell? - Defense World
Alpha Tau Receives Fda Approval to Initiate A Trial for Patients with Recurrent Glioblastoma - MarketScreener
Alpha Tau receives FDA approval to start trial for patients with recurrent GBM - TipRanks
Alpha Tau Receives FDA Approval To Initiate A Trial For Patients With Recurrent Glioblastoma - MarketScreener
Alpha Tau Medical Receives FDA Approval for Glioblastoma Trial - TipRanks
Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Recurrent Glioblastoma - GlobeNewswire
Major FDA Approval: Alpha Tau's Revolutionary Brain Cancer Treatment Advances to Human Trials - Stock Titan
Analyzing Vivos Therapeutics (NASDAQ:VVOS) and Alpha Tau Medical (NASDAQ:DRTS) - Defense World
Comprehensive Insights of the Global Vulvar Cancer Market: Key Drivers, Trends, Growth Opportunities, and F... - WhaTech
Pancreatic Ductal Adenocarcinoma Pipeline: Shaping the Future - openPR.com
Alpha Emitter Market Demand, Growth and Future Scope 2025-2032 | - openPR
HC Wainwright Forecasts Lower Earnings for Alpha Tau Medical - Defense World
Pancreatic Cancer Clinical Pipeline | 290+ Companies Advancing the Future of Treatment - openPR.com
Alpha Tau Medical’s (DRTS) Buy Rating Reaffirmed at HC Wainwright - Defense World
Q1 Virtual Investor Summit: On-Demand Presentations Now Live - The Globe and Mail
H.C. Wainwright maintains Buy on Alpha Tau stock, $9 target - Investing.com
H.C. Wainwright maintains Buy on Alpha Tau stock, $9 target By Investing.com - Investing.com UK
Promising Clinical and Regulatory Milestones Drive Buy Rating for Alpha Tau Medical Ltd. - TipRanks
Alpha Tau Medical Faces Uncertain Future Amid Clinical Trial Challenges - TipRanks
Alpha Tau Medical Reports 2024 Earnings and Clinical Progress - TipRanks
Alpha Tau Medical (NASDAQ:DRTSW) Trading Down 2.7% – Time to Sell? - Defense World
Alpha Tau Medical Reports 2024 Financial Results and Advances in Cancer Therapy Trials - TipRanks
Alpha Tau Announces Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewswire
Alpha Tau's Cancer Therapy Achieves 100% Disease Control Rate in Latest Trials - StockTitan
Alpha Emitter Market to Witness Remarkable Growth with Actinium Pharmaceutical Inc., Alpha Tau Medical Ltd - openPR
U.S. Brain Tumor Market Size & Share | Industry Report 2034 - Grand View Research
March 2025 Penny Stocks To Consider For Growth - Simply Wall St
Alpha Tau Medical to Showcase Alpha DaRT at March Investor Conferences - TipRanks
Alpha Tau to Participate in March Investor Conferences - The Manila Times
Sonodynamic Therapy Shows Promise for Glioblastoma Treatment - Targeted Oncology
Alpha Tau Medical Ltd Stock (DRTS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.39%
3.66%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):